These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 3043419

  • 21. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G.
    Vaccine; 2007 Jan 05; 25(3):490-9. PubMed ID: 16949181
    [Abstract] [Full Text] [Related]

  • 22. Host immune response to Plasmodium.
    Kabilan LS.
    Indian J Malariol; 1991 Sep 05; 28(3):189-96. PubMed ID: 1822458
    [Abstract] [Full Text] [Related]

  • 23. [NANP]19-5.1. A malaria vaccine field trial in Nigerian children.
    Reber-Liske R, Salako LA, Matile H, Sowunmi A, Stürchler D.
    Trop Geogr Med; 1995 Sep 05; 47(2):61-3. PubMed ID: 8592764
    [Abstract] [Full Text] [Related]

  • 24. Identification of key antigens of Plasmodium falciparum as vaccine candidates.
    Bushell GR, Cooper JA, Ingram LT, Schofield L, Saul A, Epping RJ, Chiu S, Jelacic S, Upcroft JA.
    P N G Med J; 1986 Mar 05; 29(1):69-73. PubMed ID: 3529708
    [No Abstract] [Full Text] [Related]

  • 25. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
    Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J.
    J Infect Dis; 1999 Nov 05; 180(5):1656-64. PubMed ID: 10515829
    [Abstract] [Full Text] [Related]

  • 26. Malaria vaccines. Are they approaching reality?
    Perlmann P.
    Nature; 1999 Nov 05; 328(6127):205-6. PubMed ID: 3299105
    [No Abstract] [Full Text] [Related]

  • 27. The comparative immunobiology of Plasmodium: model systems and new technologies in malaria vaccine research.
    Mitchell GH.
    Prog Vet Microbiol Immunol; 1987 Nov 05; 3():112-38. PubMed ID: 3078831
    [No Abstract] [Full Text] [Related]

  • 28. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
    Cryz SJ, Sadoff JC, Que JU.
    Contrib Microbiol Immunol; 1989 Nov 05; 10():166-89. PubMed ID: 2510972
    [No Abstract] [Full Text] [Related]

  • 29. Target antigens of malaria transmission blocking immunity.
    Kaushal DC, Carter R, Miller LH.
    J Commun Dis; 1987 Dec 05; 19(4):417-21. PubMed ID: 3507450
    [No Abstract] [Full Text] [Related]

  • 30. Lymphocyte responsiveness to a candidate malaria sporozoite vaccine (R32tet32) of individuals with naturally acquired Plasmodium falciparum malaria.
    Webster HK, Ho M, Looareesuwan S, Pavanand K, Wattanagoon Y, Warrell DA, Hockmeyer WT.
    Am J Trop Med Hyg; 1988 Jan 05; 38(1):37-41. PubMed ID: 3277463
    [Abstract] [Full Text] [Related]

  • 31. [A vaccine against malaria].
    Dzbeński T, Paszkowska M.
    Przegl Epidemiol; 1987 Jan 05; 41(3):249-54. PubMed ID: 3324172
    [No Abstract] [Full Text] [Related]

  • 32. Identification of a peptide sequence of the 25 kD surface protein of Plasmodium falciparum recognized by transmission-blocking monoclonal antibodies: implications for synthetic vaccine development.
    van Amerongen A, Sauerwein RW, Beckers PJ, Meloen RH, Meuwissen JH.
    Parasite Immunol; 1989 Jul 05; 11(4):425-8. PubMed ID: 2674864
    [No Abstract] [Full Text] [Related]

  • 33. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
    Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freydberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL.
    Vaccine; 2004 Apr 16; 22(13-14):1592-603. PubMed ID: 15068840
    [Abstract] [Full Text] [Related]

  • 34. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.
    Wang R, Charoenvit Y, Corradin G, Porrozzi R, Hunter RL, Glenn G, Alving CR, Church P, Hoffman SL.
    J Immunol; 1995 Mar 15; 154(6):2784-93. PubMed ID: 7876549
    [Abstract] [Full Text] [Related]

  • 35. The vaccine is dead--long live the vaccine.
    Snounou G, Rénia L.
    Trends Parasitol; 2007 Apr 15; 23(4):129-32. PubMed ID: 17300988
    [Abstract] [Full Text] [Related]

  • 36. [Vaccination: present and future].
    Piédrola Angulo G.
    An R Acad Nac Med (Madr); 1989 Apr 15; 106(2):249-69; discussion 274-6. PubMed ID: 2690673
    [No Abstract] [Full Text] [Related]

  • 37. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials.
    Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS.
    Parassitologia; 1999 Sep 15; 41(1-3):397-402. PubMed ID: 10697892
    [Abstract] [Full Text] [Related]

  • 38. [Immunology and molecular biology: targetting of a vaccine].
    Perrin LH, Mach B.
    Ther Umsch; 1986 Feb 15; 43(2):148-54. PubMed ID: 3515610
    [No Abstract] [Full Text] [Related]

  • 39. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.
    Sherwood JA, Oster CN, Adoyo-Adoyo M, Beier JC, Gachihi GS, Nyakundi PM, Ballou WR, Brandling-Bennett AD, Schwartz IK, Were JB.
    Trans R Soc Trop Med Hyg; 1991 Feb 15; 85(3):336-40. PubMed ID: 1949134
    [Abstract] [Full Text] [Related]

  • 40. Merozoite selection of erythrocytes by age and the induction of protective immunity.
    Brown KN, Carlsson J, Jarra W.
    Blood Cells; 1990 Feb 15; 16(2-3):313-8. PubMed ID: 2096982
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.